Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications

Sponsor
Albany Medical College (Other)
Overall Status
Completed
CT.gov ID
NCT03289390
Collaborator
(none)
11
1
22.9
0.5

Study Details

Study Description

Brief Summary

This study will evaluate the use of acetaminophen in preterm infants when a patent ductus arteriosus (PDA) is of concern. We will perform two simultaneous prospective observational studies over a 3 year period. The first will be of infants with clinically significant PDAs beyond 14 days of life who are medically treated with acetaminophen as a means to avoid surgical ligation, and the second will be of infants who received acetaminophen for a PDA closure during the first 2 weeks of life as a result of ibuprofen, the current standard of care in our NICU, contraindication due to medical status.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Observational
Actual Enrollment :
11 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications
Actual Study Start Date :
Aug 1, 2017
Actual Primary Completion Date :
Jun 30, 2019
Actual Study Completion Date :
Jun 30, 2019

Arms and Interventions

Arm Intervention/Treatment
Acetaminophen to close PDA

Infants with PDA treated with acetaminophen beyond 14 days of life or in whom acetaminophen is used due to contraindication to ibuprofen

Drug: Acetaminophen
Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.

Outcome Measures

Primary Outcome Measures

  1. Rate of PDA closure [3 days]

    PDA will be evaluated by echocardiography to determined whether it has closed after treatment is complete.

  2. Change in PDA size [3 days]

    Size of PDA will be measured by echocardiography to determine if the size has changed after treatment is complete.

Eligibility Criteria

Criteria

Ages Eligible for Study:
23 Weeks to 30 Weeks
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Infants born at 23 0/7 to 29 6/7 weeks gestation, with PDA determined by medical team to need treatment and infant is beyond 14 days of life.
Exclusion Criteria:
  • Congenital heart disease Pneumonia Pulmonary hypertension Pulmonary hemorrhage ALT and AST ≥ 2X the upper limit of normal (=AST> 150 U/L, ALT>90 U/L) Sepsis/meningitis Abnormal chromosomes Hydrops Major congenital malformations

Contacts and Locations

Locations

Site City State Country Postal Code
1 Albany Medical Center Albany New York United States 12208

Sponsors and Collaborators

  • Albany Medical College

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ronnelle King, MD, Albany Medical College
ClinicalTrials.gov Identifier:
NCT03289390
Other Study ID Numbers:
  • 4846
First Posted:
Sep 21, 2017
Last Update Posted:
Jan 13, 2020
Last Verified:
Jan 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 13, 2020